Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 18/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490016 | 0.88 | HCAR3 (0.60) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL14456525 | 0.87 | KDM4E (0.48) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL30864289 | 0.85 | HCAR3 (0.57) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL23675185 | 0.83 | HCAR3 (0.56) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL5441298 | 0.80 | NR4A2 (0.56) | HCAR3RXRAPPARG | |
| SCHEMBL27704159 | 0.79 | KDM4E (0.60) | HCAR3HPGDHCAR2KDM4ENPC1 | |
| SCHEMBL14400496 | 0.79 | RXRA (0.60) | HCAR3RXRA | |
| SCHEMBL12321787 | 0.77 | KMT2A (0.56) | HPGDNPC1 | |
| SCHEMBL1250337 | 0.77 | HCAR3 (0.48) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL4280123 | 0.77 | L3MBTL1 (0.57) | HCAR3HPGDHCAR2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232669-A1 | N-phenylbenzotriazolyl c-kit inhibitors | OSI PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232669-A1 | N-phenylbenzotriazolyl c-kit inhibitors | OSI PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232669-A1 | N-phenylbenzotriazolyl c-kit inhibitors | OSI PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007092403-A1 | N-PHENYLBENZOTRIAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232669-A1 | N-phenylbenzotriazolyl c-kit inhibitors | KIT, CHUK, TNNI3K | HCAR3 3267/4885HPGD 665/4885HCAR2 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.